Tags

Type your tag names separated by a space and hit enter

Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model.
World J Gastroenterol. 2008 Dec 28; 14(48):7386-91.WJ

Abstract

AIM

To discuss the expression of glactin-3 in liver metastasis of colon cancer and its inhibition by modified citrus pectin (MCP) in mice.

METHODS

Seventy-five Balb/c mice were randomly divided into negative control group (n = 15), positive control group (n = 15), low MCP concentration group (n = 15), middle MCP concentration group (n = 15) and high MCP concentration group (n = 15). CT26 colon cancer cells were injected into the subcapsule of mouse spleen in positive control group, low, middle and high MCP concentrations groups, except in negative control, to set up a colon cancer liver metastasis model. The concentration of MCP in drinking water was 0.0%, 0.0%, 1.0%, 2.5% and 5.0% (wt/vol), respectively. Liver metastasis of colon cancer was observed after 3 wk. Enzyme-linked immunosorbent assay (ELISA) was used to detect the concentration of galectin-3 in serum. Expression of galectin-3 in liver metastasis was detected by immunohistochemistry.

RESULTS

Except for the negative group, the percentage of liver metastasis in the other 4 groups was 100%, 80%, 73.3% and 60%, respectively. The number of liver metastases in high MCP concentration group was significantly less than that in positive control group (P = 0.008). Except for the negative group, the median volume of implanted spleen tumor in the other 4 groups was 1.51 cm(3), 0.93 cm(3), 0.77 cm(3) and 0.70 cm(3), respectively. The volume of implanted tumor in middle and high MCP concentration groups was significantly smaller than that in positive control group (P = 0.019; P = 0.003). The concentration of serum galectin-3 in positive control and MCP treatment groups was significantly higher than that in the negative control group. However, there was no significant difference between them. Except for the negative control group, the expression of galectin-3 in liver metastases of the other 4 groups showed no significant difference.

CONCLUSION

Expression of galetin-3 increases significantly in liver metastasis of colon cancer, which can be effectively inhibited by MCP.

Authors+Show Affiliations

Department of Abdominal Surgery, Affiliated Tumor Hospital of Guangzhou Medical College, Guangzhou 510095, Guangdong Province, China. gzdlhy@yahoo.com.cnNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19109874

Citation

Liu, Hai-Ying, et al. "Inhibitory Effect of Modified Citrus Pectin On Liver Metastases in a Mouse Colon Cancer Model." World Journal of Gastroenterology, vol. 14, no. 48, 2008, pp. 7386-91.
Liu HY, Huang ZL, Yang GH, et al. Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World J Gastroenterol. 2008;14(48):7386-91.
Liu, H. Y., Huang, Z. L., Yang, G. H., Lu, W. Q., & Yu, N. R. (2008). Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. World Journal of Gastroenterology, 14(48), 7386-91.
Liu HY, et al. Inhibitory Effect of Modified Citrus Pectin On Liver Metastases in a Mouse Colon Cancer Model. World J Gastroenterol. 2008 Dec 28;14(48):7386-91. PubMed PMID: 19109874.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibitory effect of modified citrus pectin on liver metastases in a mouse colon cancer model. AU - Liu,Hai-Ying, AU - Huang,Zhi-Liang, AU - Yang,Guo-Hua, AU - Lu,Wei-Qun, AU - Yu,Nan-Rong, PY - 2008/12/26/entrez PY - 2008/12/26/pubmed PY - 2009/5/20/medline SP - 7386 EP - 91 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 14 IS - 48 N2 - AIM: To discuss the expression of glactin-3 in liver metastasis of colon cancer and its inhibition by modified citrus pectin (MCP) in mice. METHODS: Seventy-five Balb/c mice were randomly divided into negative control group (n = 15), positive control group (n = 15), low MCP concentration group (n = 15), middle MCP concentration group (n = 15) and high MCP concentration group (n = 15). CT26 colon cancer cells were injected into the subcapsule of mouse spleen in positive control group, low, middle and high MCP concentrations groups, except in negative control, to set up a colon cancer liver metastasis model. The concentration of MCP in drinking water was 0.0%, 0.0%, 1.0%, 2.5% and 5.0% (wt/vol), respectively. Liver metastasis of colon cancer was observed after 3 wk. Enzyme-linked immunosorbent assay (ELISA) was used to detect the concentration of galectin-3 in serum. Expression of galectin-3 in liver metastasis was detected by immunohistochemistry. RESULTS: Except for the negative group, the percentage of liver metastasis in the other 4 groups was 100%, 80%, 73.3% and 60%, respectively. The number of liver metastases in high MCP concentration group was significantly less than that in positive control group (P = 0.008). Except for the negative group, the median volume of implanted spleen tumor in the other 4 groups was 1.51 cm(3), 0.93 cm(3), 0.77 cm(3) and 0.70 cm(3), respectively. The volume of implanted tumor in middle and high MCP concentration groups was significantly smaller than that in positive control group (P = 0.019; P = 0.003). The concentration of serum galectin-3 in positive control and MCP treatment groups was significantly higher than that in the negative control group. However, there was no significant difference between them. Except for the negative control group, the expression of galectin-3 in liver metastases of the other 4 groups showed no significant difference. CONCLUSION: Expression of galetin-3 increases significantly in liver metastasis of colon cancer, which can be effectively inhibited by MCP. SN - 1007-9327 UR - https://www.unboundmedicine.com/medline/citation/19109874/Inhibitory_effect_of_modified_citrus_pectin_on_liver_metastases_in_a_mouse_colon_cancer_model_ L2 - http://www.wjgnet.com/1007-9327/full/v14/i48/7386.htm DB - PRIME DP - Unbound Medicine ER -